tldrdailynews.com logo

Revolution Medicines' targeted pill delivers striking survival advantage in pancreatic cancer

1 min read
Source: statnews.com
Revolution Medicines' targeted pill delivers striking survival advantage in pancreatic cancer
Photo: statnews.com
TL;DR

In a trial for metastatic pancreatic cancer, Revolution Medicines' targeted pill daraxonrasib extended median overall survival to 13.2 months versus 6.7 months with chemotherapy, a dramatic near-doubling that experts described as very impressive.

Topics:businessbiotech#biotech#daraxonrasib#overall-survival#pancreatic-cancer#revolution-medicines#targeted-therapy
Share this article
  1. Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill  statnews.com
  2. Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial  CNBC
  3. Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer  Yahoo Finance
  4. Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial  Fierce Biotech
  5. Revolution Medicines Stock Is Soaring 38%. Here’s Why.  Barron's

Want the full story? Read the original reporting

Read on statnews.com